Au cours de chaque année académique, le département d’ophtalmologie organise, une série de 9 réunions scientifiques. L’objectif est de partager avec toute la communauté de l’ophtalmologie, des présentations de haut calibre, données par des spécialistes tant locaux qu’internationaux, invités à tour de rôle par les chefs de divisions.
Comité organisateur: Dr Patrick Hamel, professeur agrégé de clinique et chef du département d’ophtalmologie du CHU Saint-Justine & Dre Isabelle Hardy, directrice du département de l’Université de Montréal.
Le département remercie l’Association des Médecins Ophtalmologistes du Québec pour son soutient financier.
Calendrier des prochaines réunions: cliquez ici.
*** Le visionnement des conférences en différé ne donne pas le droit à des crédits ***
|12 janvier 2021
|Update on masquerade syndrome and vitreoretinal lymphoma.
Présenté par Dre Elisabetta Miserocchi (San Raffaele Scientific Institute, Milan, Italy)
Professor Elisabetta Miserocchi is a Consultant Ophthalmologist of the Ocular Immunology and Uveitis Service, based at University Hospital San Raffaele Milan, Italy in the department of Professor Francesco Bandello. After graduating with a medical degree from the University of Milan in 1996, Professor Miserocchi completed a four-year residency in the Department of Ophthalmology at the San Raffaele Scientific Institute, including a 2 two year research fellowship at the Massachusetts Eye and Ear Infirmary, part of Harvard Medical School, Massachusetts, USA with Dr. Stephen Foster.
Her main areas of interest and activity are diagnosis and treatment of uveitis, pediatric uveitis associated with rheumatic diseases, ocular cicatricial pemphigoid , herpetic ocular disease. And intraocular lymphoma. Professor Miserocchi is also currently participating to many international multicentre clinical trials on systemic immunosuppressive agents for non infectious uveitis.
Professor Miserocchi is a member of the International Uveitis Study Group and the American Uveitis Society. Professor Miserocchi is widely published in peer-reviewed journals and has presented her work at a number of national and international congresses; she was awarded the SOI-SOE Lecture at the Società Oftalmologica Italiana 2012 annual meeting in Rome for new treatments in non-infectious uveitis, and she received the American Academy of Ophthalmology Award in 2015. Dr Miserocchi has conducted research and applied new therapies to further the diagnosis and treatment of non-infectious uveitis.
|2 décembre 2020||Rétine|
|Thérapie génique de la mutation héréditaire du gène RPE65 : Une première au Canada!
Présenté par Dre Cynthia Qian et Dr Flavio Rezende (UMontréal)
Dre Cynthia Qian, MD, FRCSCEmail: email@example.com
Dr Flavio Rezende, MD, PhD
Dr Flavio Rezende, Md. PhD est professeur agrégé de clinique au Département d’ophtalmologie de l’Université de Montréal, et Ophtalmologiste chirurgien vitreo-retinien au Centre universitaire d’ophtalmologie de l’Hôpital Maisonneuve-Rosemont
|20 octobre 2020||Oculoplastie|
|Bench to Bedside: Evolution of Therapy for Thyroid Associated Ophthalmopathy
Présenté par Dr Terry Smith (Kellogg Eye Center)
Terry J. Smith, M.D.
Dr. Smith received his medical degree from the University of Missouri School of Medicine and completed his residency at the University of Illinois in Chicago and Sinai Hospital in Baltimore. He has completed fellowships in biophysics at the University of California School of Medicine, San Francisco, in molecular biochemistry at Columbia University in New York, and clinical endocrinology at the Pritzker School of Medicine, University of Chicago.
Dr. Smith is the author of over 150 articles and book chapters, and has been awarded five patents for his research discoveries. He has been elected to the Orbit Society, is chief scientific officer for the National Graves’ Foundation, and serves as reviewer for numerous scientific journals. Dr. Smith has been funded continuously by the National Institutes of Health and the Veterans Administration since 1983.
Areas of Interest
Dr. Smith’s laboratory group is interested in understanding and developing new treatments for Graves’ Disease (GD) or thyroid-associated ophthalmopathy (TAO).
Graves’ Disease is an autoimmune process directed primarily at the thyroid. Many of the patients with GD also exhibit inflammation of the tissues around the eye. Orbital manifestations of GD known as TAO, involve the dramatic remodeling of connective tissues surrounding the eye. Alterations in orbital tissue architecture can adversely affect the function and health of the eye in several ways.
There are no specific safe and effective therapies for TAO. Our overall goal is to identify the molecular and cellular mechanisms responsible for the pathogenesis of orbital involvement in TAO. We have found that patients with TAO have dramatically increased numbers of circulating fibrocytes. These fibrocytes derive from stem cells originating in the bone marrow. They infiltrate the connective tissues of the orbit. We believe that the phenotypic attributes of orbital fibroblasts underlie the propensity of the tissues surrounding the eye to become involved in GD. As a direct consequence of identifying the peculiarities exhibited by these cells, we are now in a strong position to create strategies for interrupting the disease process at a very early stage.
Their work is focused on defining the molecular targets that will lead to effective and specific therapy design.
Graves’ disease, thyroid-associated ophthalmopathy, metabolic diseases
Specialties: Endocrinology, Internal Medicine
Honors & Awards
Published Articles or Reviews
|9 juin 2020||Cornée et segment antérieur|
|La chirurgie de la cataracte bilatérale simultanée.
Présenté par Dre Marie-Ève Légaré (Université Laval)